Rhythm Pharmaceuticals (RYTM) Free Cash Flow (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) reported Free Cash Flow of -$44.2 million for Q1 2026, down 9.5% year-over-year from -$48.8 million in Q1 2025, and down 74.03% quarter-over-quarter from -$25.4 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Free Cash Flow (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 11 years of Free Cash Flow data on file, last reported at -$44.2 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$44.2 million, down 9.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$119.5 million (down 5.31% YoY), and the FY2025 annual result was -$116.6 million, down 2.41% from the prior year.
- Free Cash Flow declined to -$44.2 million in Q1 2026 per RYTM's latest filing, from -$25.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$18.8 million in Q4 2024 and troughed at -$53.8 million in Q1 2022.
- A 5-year average of -$34.3 million and a median of -$34.0 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow plunged 60.27% in 2022, then soared 37.87% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$34.0 million in 2022, then rose by 13.58% to -$29.4 million in 2023, then surged by 35.86% to -$18.8 million in 2024, then tumbled by 34.73% to -$25.4 million in 2025, then sank by 74.03% to -$44.2 million in 2026.
- Business Quant data shows RYTM's Free Cash Flow at -$44.2 million in Q1 2026, -$25.4 million in Q4 2025, and -$26.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn | -44.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.19 Mn |
| Mar 31, 2026 | -44.19 Mn |
| Dec 31, 2025 | -25.39 Mn |
| Dec 31, 2025 | -25.39 Mn |
| Sep 30, 2025 | -26.62 Mn |
| Sep 30, 2025 | -26.62 Mn |
| Jun 30, 2025 | -23.31 Mn |
| Jun 30, 2025 | -23.31 Mn |
| Mar 31, 2025 | -40.35 Mn |
| Mar 31, 2025 | -40.35 Mn |
| Dec 31, 2024 | -18.85 Mn |
| Dec 31, 2024 | -18.85 Mn |
| Sep 30, 2024 | -25.22 Mn |
| Sep 30, 2024 | -25.22 Mn |
| Jun 30, 2024 | -29.08 Mn |
| Jun 30, 2024 | -29.08 Mn |
| Mar 31, 2024 | -40.74 Mn |
| Mar 31, 2024 | -40.74 Mn |
| Dec 31, 2023 | -29.38 Mn |
| Dec 31, 2023 | -29.38 Mn |